GRF Peptide Analog for Muscle Function in Wasting Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current growth hormone replacement therapies often result in inconsistent improvements in muscle function for patients with wasting conditions, such as COPD and HIV, despite increasing lean body mass, indicating a need for therapeutics that effectively enhance both muscle mass and functionality.
Innovation Solution
Administration of GH secretagogues, specifically GRF or its analogs, such as the GRF peptide with a hydrophobic tail anchored via an amide bond, to increase muscle function, including muscle strength and endurance, and reduce discomfort in patients with wasting conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant human growth hormone (rhGH) replacement therapy is administered to patients with wasting conditions, then lean body mass increases, but muscle function improvement is inconsistent and variable
Solution Approach 1:
The patent changes the therapeutic parameter from direct GH administration to GH secretagogue administration (GRF or analogs), which indirectly stimulates GH release. This parameter change results in more consistent muscle function improvement while maintaining lean body mass gains, as the secretagogues produce a more physiological pattern of GH secretion
Solution Approach 2:
The patent introduces GH secretagogues (GRF or analogs) as an intermediary substance that mediates between the administered therapy and the target effect. Instead of directly administering GH, the secretagogue stimulates the body's own GH release, creating a more reliable and consistent therapeutic response for muscle function improvement
2Quantity of substance
If nutritional repletion and anabolic steroids are administered to promote muscle gain, then some muscle mass increase occurs, but muscle function improvement is limited
Solution Approach 1:
The patent changes the therapeutic approach from nutritional repletion or anabolic steroids to GH secretagogues, which activate the endogenous GH-IGF-1 axis. This parameter change produces superior muscle function improvement alongside muscle mass gain, as evidenced by enhanced muscle strength, endurance, and reduced discomfort in wasting patients
3Quantity of substance
If short term growth hormone administration is given to patients with COPD, then lean body mass increases, but functional improvement is inconsistent
Solution Approach 1:
The patent uses GH secretagogues as intermediaries to stimulate endogenous GH release, producing more sustained and consistent functional improvements. The secretagogues create a physiological feedback loop that maintains therapeutic effects longer than direct GH administration, particularly for muscle function parameters in COPD patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases serum IGF-1 levels, augments lean body mass, decreases fat mass, and improves muscle strength and endurance in patients with wasting conditions, as demonstrated by the administration of (hexenoyl trans-3)hGRF(1-44)NH2, a synthetic human growth hormone releasing factor analog.
Implementation Method 1
a GRF peptide with a hydrophobic tail anchored via an amide bond
Data Source
AI summary
The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.